title: Biochemical evaluation of the antiplatelet effect of aspirin in patients at different levels of cardiovascular risk.
abstract: BACKGROUND
  The phenomenon called aspirin resistance is being intensively discussed.
  
  
  METHODS
  To evaluate the biochemical aspirin response, the method of urinary 11-dehydro TXB2 levels measurement was used. Quantitative detection of TXB2 in urine was determined by competitive enzyme immunoassay, using human Thromboxane B2 ELISA-kit. We investigated the urine samples from 69 patients.
  
  
  RESULTS
  The mean urinary levels of 11-dehydro TXB2 were significantly lower in patients in the primary and secondary types of aspirin prevention comparing with the control group of patients not taking aspirin. The difference in thromboxane concentrations between the two groups of patients taking aspirin did not reach statistical significance. Our results did not show significant differences in the biochemically measured aspirin response when comparing diabetics with non-diabetics. Similarly, the observed tendency to higher thromboxane levels in women did not show to be significantly different from men.
  
  
  CONCLUSIONS
  Our pilot study did not show any significant differences among patients at different cardiovascular risk. Since there is currently no standard laboratory method to detect aspirin non-responders available, the term aspirin resistance remains controversial and requires further research. Every effort should be done to improve patients' compliance and to prevent clinically relevant interactions of aspirin with ibuprofen. The elimination of these two factors as was the case in our study may provide better efficacy of the antithrombotic prevention by aspirin (Fig. 2, Tab. 4, Ref. 19). Full Text (Free, PDF) www.bmj.sk.
authors.affiliation: Department of Pharmacology, Faculty ofMedicine, Comenius University, Bratislava, Slovakia. jan.rajec@fmed.uniba.sk
authors.forename: J
authors.initials: J
authors.lastname: Rajec
authors.forename: M
authors.initials: M
authors.lastname: Kriska
authors.forename: R
authors.initials: R
authors.lastname: Vojtko
authors.forename: A
authors.initials: A
authors.lastname: Dukat
authors.forename: Z
authors.initials: Z
authors.lastname: Risnyovszki
authors.forename: M
authors.initials: M
authors.lastname: Sapak
mesh_terms: D000368:Aged; D001241:Aspirin / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D003920:Diabetes Mellitus / Q000652:urine; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D012306:Risk; D013929:Thromboxane B2 / Q000031:analogs & derivatives* / Q000652:urine
chemical_list: D010975:Platelet Aggregation Inhibitors; D013929:Thromboxane B2; C049235:11-dehydro-thromboxane B2; D001241:Aspirin